ImmunoPrecise Antibodies Ltd.

TSXV:IPA 주식 보고서

시가총액: CA$162.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ImmunoPrecise Antibodies 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

0%

부채 비율

CA$0

부채

이자 보상 비율n/a
현금CA$19.24m
주식CA$66.24m
총 부채CA$13.70m
총 자산CA$79.94m

최근 재무 상태 업데이트

Recent updates

We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Oct 20
We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

Dec 23
Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Nov 25
Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

재무 상태 분석

단기부채: IPA's short term assets (CA$27.1M) exceed its short term liabilities (CA$5.4M).

장기 부채: IPA's short term assets (CA$27.1M) exceed its long term liabilities (CA$8.3M).


부채 대 자본 내역 및 분석

부채 수준: IPA is debt free.

부채 감소: IPA had no debt 5 years ago.


대차 대조표


현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: IPA has less than a year of cash runway based on its current free cash flow.

예측 현금 활주로: IPA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 36% each year


건강한 기업 발견하기